December 2002 in “Operative Techniques in Otolaryngology-Head and Neck Surgery” Hair loss from trauma can be managed using scalp expansion, flaps, and hair transplants to improve appearance and well-being.
The book details advanced techniques in cosmetic dermatology for experienced surgeons.
Abortion access should be defended on public health grounds, and medical evaluations are crucial in psychiatric cases to avoid misdiagnosis.
Both books are valuable resources in their fields.
The document reviewed various health-related books, focusing on abortion debates, medical conditions, and effective health communication.
March 1997 in “The American Journal of Cosmetic Surgery” A new hair transplant method showed promising results and a study found how deep a CO₂ laser can penetrate skin.
December 2020 in “Actas Dermo-Sifiliográficas” LLLT increases hair density and growth in AGA patients.
July 2020 in “Environmental Science and Pollution Research” Finasteride harms invertebrates' survival and burial ability.
April 2019 in “Journal of emerging technologies and innovative research” Early treatment of Female Pattern Hair Loss is important to stop it from getting worse, and various treatments can help, especially in mild to moderate cases.
January 2017 in “Cogent Medicine” Extracts improve hair growth in alopecia.
AGA causes permanent hair loss; women use 2% minoxidil, men use 1 mg finasteride daily.
April 2008 in “Blackwell Publishing Ltd eBooks” AGA causes permanent hair loss; minoxidil helps men, finasteride helps men, minoxidil somewhat helps women, estrogens/antiandrogens lack evidence for women.
June 2001 in “International Journal of Cosmetic Surgery and Aesthetic Dermatology” Finasteride improves hair growth in men with androgenetic alopecia.
September 2010 in “International Journal of Cosmetic Science” Chemical treatments change hair surface properties, making it more hydrophilic and able to bind conditioners.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
13 citations
,
January 2005 in “Chemical and Pharmaceutical Bulletin” Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
28 citations
,
September 2000 in “Journal of Medicinal Chemistry” Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
March 2025 in “International Journal For Multidisciplinary Research” Computational techniques can improve drug development for treating certain conditions.
64 citations
,
March 2008 in “Neuropsychopharmacology” January 2018 in “ScholarWorks @UVM (University of Vermont)” Selenium in proteins helps prevent over-oxidation and supports chemical reversibility.
3 citations
,
August 2010 in “Letters in Drug Design & Discovery”
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
4 citations
,
April 1955 in “Textile Research Journal” The effectiveness of reducing agents on hair fibers depends on their electrode potentials.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
July 2013 in “Edinburgh Research Archive (University of Edinburgh)” Dutasteride may reduce insulin sensitivity and increase body fat.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
6 citations
,
March 2003 in “Archiv Der Pharmazie” Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.
January 2009 in “Journal of Xingtai University” Finasteride is made through a series of chemical reactions starting from a specific intermediate compound.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.